| Autor: |
Annelies Boonen, Atul Deodhar, Martin Rudwaleit, Lianne S Gensler, Karl Gaffney, Maureen Dubreuil, Victoria Navarro-Compán, Vanessa Taieb, Carmen Fleurinck, Ute Massow, Thomas Vaux, Michael F Mørup, Christine de la Loge |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
RMD Open, Vol 10, Iss 2 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2056-5933 |
| DOI: |
10.1136/rmdopen-2024-004202 |
| Popis: |
Objective To assess the impact of bimekizumab on physical functioning, sleep, work productivity and overall health-related quality of life (HRQoL) in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA) in the phase 3 studies BE MOBILE 1 and 2.Methods Patients were randomised to subcutaneous bimekizumab 160 mg or placebo every 4 weeks; from Week 16, all patients received bimekizumab 160 mg every 4 weeks. We report the following outcomes to Week 52: Bath Ankylosing Spondylitis Functional Index (BASFI), Medical Outcomes Study Sleep Scale Revised (MOS-Sleep-R) Index II, Work Productivity and Activity Impairment: axSpA (WPAI:axSpA), Short Form-36 Physical and Mental Component Summary (SF-36 PCS/MCS) and Ankylosing Spondylitis Quality of Life (ASQoL).Results At Week 16, bimekizumab-randomised patients demonstrated significantly greater improvement from baseline versus placebo in BASFI, SF-36 PCS and ASQoL (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
